Dutch-US Research Team IDs Putative Protein Profile of Tamoxifen Resistance in Breast Cancer | GenomeWeb

This story has been updated from a version originally posted on June 16.

Tamoxifen is among the most successful breast cancer therapies, but in about 25 to 35 percent of patients — including half of those who have recurrent disease — the selective estrogen receptor modulator marketed by AstraZeneca has no therapeutic effect.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.